Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 12/20 | 0.54 |
| ▸ | KDR | P35968 | 9/20 | 0.54 |
| ▸ | RET | P07949 | 6/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.43 |
| ▸ | CLK2 | P49760 | 2/20 | 0.43 |
| ▸ | CLK3 | P49761 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morpholine SCHEMBL5822017 | 0.96 | CDK1 (0.51) | CDK1KDRRETERBB2GRM4 | |
| SCHEMBL4035045 | 0.93 | CDK1 (0.57) | CDK1KDRRETERBB2CLK2 | |
| SCHEMBL4033921 | 0.92 | CDK1 (0.56) | CDK1KDRRETERBB2CLK2 | |
| SCHEMBL13797810 | 0.92 | CDK1 (0.56) | CDK1KDRRETERBB2GRM4 | |
| Pyrrolidine SCHEMBL5820833 | 0.90 | CDK1 (0.53) | CDK1KDRRETERBB2CLK2 | |
| Piperidine SCHEMBL5823118 | 0.89 | CDK1 (0.52) | CDK1KDRRETERBB2CLK2 | |
| SCHEMBL19497652 | 0.86 | WNT1 (0.46) | RETGRM4CLK2CLK3DYRK1A | |
| SCHEMBL4033912 | 0.85 | CDK1 (0.72) | CDK1KDRRETERBB2CLK2 | |
| SCHEMBL12370327 | 0.84 | CLK2 (0.56) | CLK2CLK3DYRK1A | |
| SCHEMBL4035660 | 0.84 | CDK1 (0.53) | CDK1KDRRETERBB2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541367-B2 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-02 | — | — | US | claimed |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-19 | — | — | US | claimed |
| WO-2006130673-A1 | 3-BENZOIMIDAZOLYL-PYRAZOLOPYRIDINES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-07 | — | — | WO | claimed |
| US-7541367-B2 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-02 | — | — | US | disclosed |
| US-7541367-B2 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-02 | — | — | US | disclosed |
| US-7541367-B2 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-02 | — | — | US | disclosed |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | PRKDC, PRKACA, ABL1 | CDK1 307/4885KDR 641/4885RET 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.